Fasoracetam.
Research-backed compound with potential health benefits. Aims to reduce anxiety and improve focus. It works on the brain's GABA system, which is like your body's natural 'chill out' signal.
Reviewed March 2026
- Category
- Compound
What Fasoracetam is, and what it does.
- Does it work
- It suits experienced self experimenters who read the primary literature and accept that 44 published records is a thin base. If you want settled human evidence, it is not there yet.
- How much to take
- Start low. 10-20mg, once or twice a day. Since there are no official guidelines, less is more. Requires a milligram scale.
- Time to feel it
- Users describe something within the first few days at a steady daily amount, and the small clinical work ran over weeks. Nobody has mapped a proper onset curve for it yet.
- The first dose
- You might feel a subtle lift in mood or a smoother train of thought. Or you might feel nothing. Don't expect a lightning bolt.
- With regular use
- Consistent users report sustained improvements in anxiety and cognitive function after a few weeks. This is based on user reports, not solid clinical trials.
- How well tolerated
- The big unknown. Short-term seems okay for most, but long-term data is missing. It's a research chemical for a reason.
- How it feels
- A clean, calm focus. Like your baseline anxiety is turned down a notch, letting you think more clearly. Not a stimulant buzz.
- The overlooked benefit
- It was built as a repeated dose compound. The receptor changes described in preclinical work appear after days of dosing, not from a single capsule, so day one tells you little.
20 to 100mg a day is where Fasoracetam works.
Source: Elia et al., Nat Commun, 2018 (ADHD trial)
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Fasoracetam is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Attention and cognitive performanceNarrative review
- Metabotropic glutamate receptor signallingAnimal study
- GABA-B receptor response after repeated dosingAnimal study
- Stress related behaviour in animal modelsAnimal study
- Cholinergic signalling alongside choline supplyAnimal study
Questions people ask about Fasoracetam.
- Is this legal to buy?
- In the US, it's in a grey area. Sold as a 'research chemical not for human consumption'. It's not a controlled substance.
- Will it show up on a drug test?
- Highly unlikely. Standard drug panels don't screen for racetam compounds.
- Can I take it with my antidepressant?
- Absolutely talk to your doctor first. Messing with brain chemistry is serious business. Don't mix without medical advice.
- Is it addictive?
- Doesn't appear to be physically addictive. Some users report tolerance, suggesting that taking breaks (cycling) is a smart move.
- How is it different from Piracetam?
- It works more on the GABA system, making it potentially better for anxiety. Piracetam is more of a general cognitive enhancer.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Racetam compounds raise acetylcholine turnover at the synapse, which draws on free choline. Alpha-GPC supplies choline that crosses into the brain, which is why the pairing is standard formulation practice.
Citicoline delivers both choline for acetylcholine synthesis and cytidine for membrane phospholipid turnover. Both are drawn on more heavily when cholinergic transmission is stimulated by a racetam.
Acetylcholine is assembled from choline and acetyl coenzyme A, and choline availability is the limiting input. Raising cholinergic turnover without added choline draws the pool down.
Cognizin is a standardised citicoline that feeds the same choline and cytidine pools. It is paired with racetams for the same substrate reason.
Huperzine A slows acetylcholinesterase, so released acetylcholine persists longer in the cleft, while a racetam raises release and receptor sensitivity. The two act at different points of the same cholinergic step, so cumulative cholinergic load should be watched.
Both are pyrrolidone racetams that modulate glutamatergic and cholinergic transmission. Stacked together their cholinergic demand adds, which is why choline is usually added alongside.
Noopept is a peptide-shaped racetam analogue that also modulates glutamate receptor signalling. Combined use raises the shared cholinergic and glutamatergic load rather than acting through separate systems.
Fasoracetam acts on metabotropic glutamate receptor signalling, and magnesium sits in the NMDA channel pore regulating glutamatergic tone. Both touch glutamate transmission from different sides.
Pantothenic acid is the backbone of coenzyme A, and acetyl-CoA is the acetyl donor that choline acetyltransferase uses to build acetylcholine. Racetam-class compounds are studied for their effects on cholinergic signalling, so the substrate side of that pathway matters. The pairing is a cofactor relationship rather than a tested combination.
Acetyl-L-carnitine carries an acetyl group that can enter the acetyl-CoA pool used for acetylcholine synthesis, alongside its role in shuttling fatty acids into mitochondria. Formulators pair it with racetam-class compounds for that acetyl-donor role. No combination trial is being described here, only the shared biochemistry.
L-theanine is a glutamate analogue with weak activity at glutamate receptor sites and is commonly used for its calming profile. Fasoracetam is characterised in preclinical work as acting on glutamatergic and GABAergic receptor systems, so the two touch overlapping targets. Read this as mechanistic overlap rather than a measured clinical result.
Caffeine blocks adenosine receptors and raises overall cortical arousal, which can stack with a glutamatergic nootropic on subjective stimulation. People who combine them often report over-stimulation at doses each is tolerable alone. This is a flag about additive stimulation, not a claim of enhanced effect.
Phosphatidylserine is a structural phospholipid of neuronal membranes and influences the lipid environment in which receptors sit. Racetam-class compounds are proposed to act at membrane-embedded receptor systems. The pairing is a formulation convention in nootropic blends and rests on membrane biology rather than on a combination study.
DHA is the dominant long-chain polyunsaturated fatty acid in neuronal membrane phospholipids and shapes membrane fluidity and synaptic structure. Any compound acting at synaptic receptors operates inside that membrane. The relationship is structural biochemistry, not a tested pairing.
Bacopa is studied for cholinergic and synaptic-plasticity effects on memory-related measures. Fasoracetam sits in the same nootropic use category, so blends often carry both. There is no combination evidence, and the overlap is mechanistic.
Lion's mane is studied for neurotrophic signalling in preclinical models, a different mechanism from receptor modulation. Nootropic stacks combine the two on the assumption that trophic and receptor-level routes are complementary. That assumption has not been measured in a combination trial.
L-tyrosine is the direct precursor for dopamine and noradrenaline through tyrosine hydroxylase and the downstream decarboxylation and beta-hydroxylation steps. Catecholamine availability shapes the attentional side of any cognitive stack. The relationship is precursor supply, not a demonstrated interaction with fasoracetam.
Vitamin B12 supports methionine synthase, and the methyl groups from that cycle feed phosphatidylcholine synthesis by the PEMT route, which is one internal source of choline. Choline availability is the substrate side of cholinergic signalling. This is standard one-carbon biochemistry rather than a fasoracetam-specific finding.
5-methyltetrahydrofolate donates the methyl group that regenerates methionine, and methionine feeds S-adenosylmethionine, the universal methyl donor used in neurotransmitter turnover. Blends that push cholinergic and monoamine pathways draw on that pool. The connection is settled biochemistry, not a combination result.
Creatine buffers ATP through the phosphocreatine system, including in neural tissue, which is the energetic side of sustained cognitive work. Fasoracetam acts on receptor signalling, a different level entirely. Any combined benefit is inferred from separate literatures rather than measured together.
Rhodiola is studied for effects on perceived fatigue under load and is a common stack partner in cognitive formulas. The mechanisms proposed for it involve monoamine handling and stress-axis signalling, not glutamate receptors. Combining them is a formulation convention with no combination data.
Nothing specific on file for Fasoracetam. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Fasoracetam actually does.
It is a lab-made molecule in the same chemical family as piracetam.
The body builds acetylcholine from choline plus an acetyl group, so both substrates have to be available.
Animal work describes it acting on glutamate and GABA receptor systems, which is why it sits in the glutamatergic nootropic group.
It dissolves in water, so it does not need to be taken with fat.
Where Fasoracetam comes from.
It is made in a chemical plant from petrochemical building blocks, in several reaction steps, then crystallised and tested. Nothing about it comes from a plant or an animal.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The starting materials are commodity organic intermediates, including a pyrrolidinone-type lactam building block and a piperidine unit, both made at industrial scale from petrochemical feedstocks rather than from any plant or animal source.
The lactam ring and the piperidine carbonyl group are joined through a sequence of condensation and coupling steps under controlled temperature and solvent conditions, with intermediates isolated between stages.
Crude product is recrystallised to remove unreacted starting material, by-products and residual solvent; the solid that comes out of an aqueous or aqueous-solvent system is typically the monohydrate.
Batches are checked by chromatographic assay for identity and purity and for residual solvent, since a chemically synthesised active has no botanical marker to standardise against.
The dried crystalline solid is milled and either sold as a bulk powder or filled into capsules, usually with a flow agent or a bulking excipient because the active dose is small.
The forms it comes in.
The studies, linked.
1 source behind our Fasoracetam verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialA Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion SyndromeClinicalTrials.gov ↗PHASE2 · 37 participants · Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.